The Big Spend-Down: US FDA Eyes $159M Reduction In Carryover User Fees
Agency will substantially reduce amount of human drug and biosimilar user fees that it carries over from year to year by the end of fiscal 2022; carryover generic drug and biosimilar fees will go toward hiring term-limited employees and building capacity, but a technical issue will keep FDA from accessing $79m in PDUFA fees.
You may also be interested in...
FDA May Not Implement User Fee Workload Adjuster In PDUFA VI
Three-to-five year timeline needed to develop algorithms does not engender confidence that new version of formula, which historically pushed user fee rates higher, will be ready before PDUFA VII begins.
Biosimilar User Fee Agreement Offers FDA Funding Boost, Fee Structure Overhaul
BsUFA revenue amounts and fees will be separated from PDUFA and relative contribution of each fee type to the overall pot will change; user fee revenue target for program's first year is $45m.
Biosimilar User Fee Collections Rise, But Little Spent On Program Costs
FDA attributes large carryover balance to uncertainty in knowing when it has reached statutory funding threshold that triggers access to fees.